Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Cambridge, GBR
Babraham Research Campus
Babraham
Cambridge, CB22 3AT, GBR

People

Funding

TOTAL $4.7M
FUNDING TOTAL $4.7M
Series A, 11/2012
Parkwalk Advisors Ltd
Series B, 11/2013
Parkwalk Advisors Ltd
£1.8M
Seed, 12/2013
£1.3M

Tags

Definigen

Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.

Recent Milestones

Videos

Screenshots

Definigen screenshot
Above: Homepage
Uploaded: 12/12/13

Sources

  1. The University of Cambridge Enterprise Fund has made its first investments in three companies: Cambridge CMOS Sensors, Inotec AMD and DefiniGEN. (enterprise.cam.ac.uk) [edit]
  2. Citation Needed [add]
  3. Definigen raises £1.3m for stem cell advance (businessweekly.co.uk) [edit]
Edit This Page
Last Edited 4/3/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy